Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis

Natalizumab (TYSABRI®) was the first high-efficacy monoclonal antibody disease-modifying therapy (DMT) approved as a monotherapy for the treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressi...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Leary, Shirley, Brugger, Helen T., Wallentine, Dale, Sershon, Lisa, Goff, Erica, Saldana-King, Toni, Beavin, Jill, Avila, Robin L., Rutledge, Danette, Moore, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health, Inc. 2023
Materias:
Features
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635346/
https://www.ncbi.nlm.nih.gov/pubmed/37920108
http://dx.doi.org/10.1097/NAN.0000000000000519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635346/
https://www.ncbi.nlm.nih.gov/pubmed/37920108
http://dx.doi.org/10.1097/NAN.0000000000000519

Ejemplares similares